Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

Thomas Ryckmans(Pfizer (United Kingdom)), Tim Young(Pfizer (United Kingdom)), Ana Monica Correia(Pfizer (United Kingdom)), Dafydd R. Owen(Pfizer (United States)), Isabelle Tran(Pfizer (United Kingdom)), Val A. Horne(Pfizer (United Kingdom)), Michelle F. Tutt(Pfizer (United Kingdom)), Martin P. Edwards(Pfizer (United States)), Lisa R. Thompson(Pfizer (United Kingdom))
Bioorganic & Medicinal Chemistry Letters
May 22, 2009
10.1016/j.bmcl.2009.05.062
Cited by 269

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382
Lipophilic Efficiency as an Important Metric in Drug Design
|Journal of Medicinal Chemistry|2018|340